Media headlines about CytomX Therapeutics (NASDAQ:CTMX) have trended somewhat positive on Monday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CytomX Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 44.8506785855211 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
CTMX has been the topic of several analyst reports. BidaskClub lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Bank of America boosted their target price on CytomX Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Zacks Investment Research downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Jefferies Group boosted their target price on CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Finally, Cantor Fitzgerald set a $40.00 target price on CytomX Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $37.86.
Shares of CTMX opened at $28.45 on Monday. The company has a market capitalization of $1,098.48, a PE ratio of -24.53 and a beta of 0.76. CytomX Therapeutics has a one year low of $13.00 and a one year high of $35.00.
In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 13,052 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $21.04, for a total transaction of $274,614.08. Following the transaction, the insider now owns 17,695 shares of the company’s stock, valued at approximately $372,302.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Debanjan Ray sold 2,500 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $21.11, for a total value of $52,775.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 132,626 shares of company stock worth $3,758,030. Company insiders own 4.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “CytomX Therapeutics (CTMX) Earning Somewhat Favorable Media Coverage, Study Finds” was posted by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.wkrb13.com/2018/04/02/cytomx-therapeutics-ctmx-earning-somewhat-favorable-media-coverage-study-finds.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.